SynCore Biotechnology Co.,Ltd (TPEX:4192)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
20.90
-0.30 (-1.42%)
Mar 10, 2026, 1:16 PM CST
-39.07%
Market Cap 745.50M
Revenue (ttm) 26.26M
Net Income (ttm) -46.41M
Shares Out 35.17M
EPS (ttm) -1.32
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 6,631
Average Volume 14,769
Open 21.10
Previous Close 21.20
Day's Range 20.90 - 21.10
52-Week Range 19.50 - 35.80
Beta 0.33
RSI 39.54
Earnings Date Mar 13, 2026

About TPEX:4192

SynCore Biotechnology Co.,Ltd, engages in development and sale of food advisory, medicine inspection, and biotechnology service in Taiwan. The company is involved in the development of SB01, an injectable anti-cancer new ingredient (NCE) that is in Phase II clinical trials for the treatment of head and neck cancer; and SB02, an anti-cancer NCE, which is in preclinical research for use in the treatment of stomach cancer. It also offers SB03-Veregen, an ointment for the treatment of patients with external genital and perianal warts EGW; and SB04,... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 40
Stock Exchange Taipei Exchange
Ticker Symbol 4192
Full Company Profile

Financial Performance

In 2024, TPEX:4192's revenue was 23.34 million, an increase of 15.55% compared to the previous year's 20.20 million. Losses were -54.28 million, 42.2% more than in 2023.

Financial Statements

News

There is no news available yet.